HOME >> MEDICINE >> NEWS
Takeda responds to the FDA advisory committee recommendation

Deerfield, IL, July 30, 2007 Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS ; (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

The breadth and depth of ACTOS data encompassing more than 16,000 patients over the past 10 yearsis consistent: Short- and long-term studies, both prospective and observational, studies in both humans and animals, all have shown no evidence that ACTOS is associated with an increased risk of heart attack or stroke, said Mehmood Khan, M.D., TGRD president. Critical in this body of data is the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study, since the only scientific way to determine a medications safety is a prospective, long-term trial.

About the PROactive Study

PROactive was a prospective, randomized, placebo-controlled outcomes trial. The PROactive study included 5,238 patients with type 2 diabetes and a history of macrovascular disease, who were force titrated up to 45 mg daily of either ACTOS or placebo. In this study, there was no difference in the number of macrovascular events between standard of care and ACTOS, and standard of care alone. Although there was no statistically significant difference between ACTOS and standard of care for the primary endpoint, there was no increase in mortality or total macrovascular events with ACTOS.

The ACTOS Prescribing Information was recently revised by the FDA to include this reassuring cardiovascular safety data. ACTOS is the only thiazolidinedione (TZD) with safety data from a cardiovascular outcomes trial in its label.

Although drugs may be in the same class, they also can have different clinical effects due to differences
'"/>

Contact: Cristina Sotolongo
Cristina.Sotolongo@ketchum.com
646-935-4021
Ketchum
30-Jul-2007


Page: 1 2

Related medicine news :

1. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
2. Takeda submits new drug application for combination type 2 diabetes medication
3. Stubborn ulcerative colitis responds to arthritis drug, review finds
4. American Egg Board responds to proposed USDA rule to revise WIC food package
5. Bradley Hospital responds to FDA report on ADHD drugs
6. Life-threatening lupus responds to stem cell transplant therapy
7. Pain research using electronic diaries helps identify who responds to placebo effect
8. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
9. ARRS president responds to NAS report on ionizing radiation
10. Medical, IT, engineering experts form advisory panel for electronic health record safety
11. National Academies advisory: Native African vegetables

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
Cached News: